Peter Ansell

4.4k total citations · 1 hit paper
89 papers, 1.9k citations indexed

About

Peter Ansell is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Ansell has authored 89 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 29 papers in Genetics and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Ansell's work include Glioma Diagnosis and Treatment (27 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Treatment and Pharmacology (14 papers). Peter Ansell is often cited by papers focused on Glioma Diagnosis and Treatment (27 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Treatment and Pharmacology (14 papers). Peter Ansell collaborates with scholars based in United States, Netherlands and Australia. Peter Ansell's co-authors include Yunli Zhou, Dalia L. Batista, Roger Gejman, Anne Klibanski, Yingying Wang, Ying Zhong, Xun Zhang, Jing Zhao, Lisa Roberts-Rapp and Hao Xiong and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Peter Ansell

87 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of p53 by MEG3 Non-coding RNA

2007 544 citations Yunli Zhou, Dalia L. Batista et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Ansell United States	22	965	675	569	298	227	89	1.9k
Josef Brueggen Switzerland	10	1.8k 1.9×	381 0.6×	633 1.1×	230 0.8×	348 1.5×	14	2.4k
Stephen Leong United States	23	842 0.9×	606 0.9×	1.1k 2.0×	167 0.6×	471 2.1×	73	2.3k
Jane Kendrew United Kingdom	22	1.5k 1.6×	561 0.8×	1.1k 1.9×	144 0.5×	638 2.8×	33	2.7k
Heikki J. Helin Finland	25	1.0k 1.1×	571 0.8×	574 1.0×	249 0.8×	503 2.2×	38	2.1k
Debyani Chakravarty United States	17	856 0.9×	776 1.1×	602 1.1×	264 0.9×	411 1.8×	35	1.9k
Sidong Huang Canada	22	1.9k 1.9×	621 0.9×	1.2k 2.0×	204 0.7×	404 1.8×	44	2.9k
Ben Markman Australia	24	1.3k 1.4×	329 0.5×	1.2k 2.1×	229 0.8×	489 2.2×	75	2.5k
Francesco Galimi Italy	24	1.1k 1.2×	458 0.7×	1.2k 2.0×	82 0.3×	444 2.0×	35	2.5k
Vanessa Rodrik-Outmezguine United States	16	2.1k 2.2×	458 0.7×	943 1.7×	233 0.8×	561 2.5×	32	2.8k
Ka Yin Kwong United States	14	1.7k 1.8×	353 0.5×	1.2k 2.1×	140 0.5×	310 1.4×	17	2.7k

Countries citing papers authored by Peter Ansell

Since Specialization

Citations

This map shows the geographic impact of Peter Ansell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ansell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ansell more than expected).

Fields of papers citing papers by Peter Ansell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ansell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ansell. The network helps show where Peter Ansell may publish in the future.

Co-authorship network of co-authors of Peter Ansell

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ansell. A scholar is included among the top collaborators of Peter Ansell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ansell. Peter Ansell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baijal, Shobhit, Jiebo Luo, Nan Zhang, et al.. (2024). 1379P c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study. Annals of Oncology. 35. S866–S866. 1 indexed citations

Wang, Shui, Aiping Luo, Nusrat Choudhury, et al.. (2024). P3.13D.09 Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S363–S363.

Bar, Jair, Shobhit Baijal, Weidong Zhao, et al.. (2023). 1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort. Annals of Oncology. 34. S799–S800. 2 indexed citations

Cho, Byoung Chul, Melissa L. Johnson, Jair Bar, et al.. (2023). 655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC). Annals of Oncology. 34. S460–S461. 5 indexed citations

Ansell, Peter, D. Ross Camidge, Shobhit Baijal, et al.. (2023). Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens.. Journal of Clinical Oncology. 41(16_suppl). e21105–e21105. 1 indexed citations

You, Benoît, Vasudha Sehgal, Balakrishna Hosmane, et al.. (2022). CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. Journal of Clinical Oncology. 41(1). 107–116. 20 indexed citations

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2021). A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine. 62(6). 787–794. 15 indexed citations

Anderson, Mark G., Qian Zhang, Luis E. Rodrı́guez, et al.. (2021). ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer. 21(1). 681–681. 9 indexed citations

Vaidya, Kedar S., Michael J. Mitten, Anatol Oleksijew, et al.. (2021). Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. Journal of Neuro-Oncology. 152(2). 233–243. 9 indexed citations

10.

Strickler, John H., Patricia LoRusso, Ravi Salgia, et al.. (2020). Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 19(5). 1210–1217. 21 indexed citations

11.

Lassman, Andrew B., Lisa Roberts-Rapp, И. А. Соколова, et al.. (2019). Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research. 25(11). 3259–3265. 25 indexed citations

12.

French, Pim J., Marica Eoli, Juan Manuel Sepúlveda-Sánchez, et al.. (2019). Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology. 21(10). 1263–1272. 28 indexed citations

13.

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2017). A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806. Internal Medicine Journal. 47. 13–13. 2 indexed citations

14.

Bent, Martin J. van den, Lisa Roberts-Rapp, Peter Ansell, et al.. (2017). Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma. Annals of Oncology. 28. v110–v110. 1 indexed citations

15.

Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations

16.

Reardon, David A., Andrew B. Lassman, Martin J. van den Bent, et al.. (2016). Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. 19(7). now257–now257. 86 indexed citations

17.

Dumontier, Michel, Alison Callahan, José Cruz-Toledo, et al.. (2014). Bio2RDF release 3: a larger connected network of linked data for the life sciences. Research Publications (Maastricht University). 401–404. 26 indexed citations

18.

Willighagen, Egon, Andra Waagmeester, Ola Spjuth, et al.. (2013). The ChEMBL database as linked open data. Journal of Cheminformatics. 5(1). 23–23. 78 indexed citations

19.

Callahan, Alison, et al.. (2012). Improved Dataset Coverage and Interoperability with Bio2RDF Release 2.. Research Publications (Maastricht University). 1 indexed citations

20.

Batista, Dalia L., Xun Zhang, Roger Gejman, et al.. (2006). The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. 91(11). 4482–4488. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact